A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,109,279 shares of PHAT stock, worth $76.9 Million. This represents 9.84% of its overall portfolio holdings.

Number of Shares
10,109,279
Previous 10,109,279 -0.0%
Holding current value
$76.9 Million
Previous $104 Million 75.53%
% of portfolio
9.84%
Previous 6.14%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$7.28 - $14.32 $12.4 Million - $24.4 Million
1,702,127 Added 20.25%
10,109,279 $145 Million
Q3 2022

Nov 14, 2022

BUY
$6.46 - $12.11 $16.7 Million - $31.2 Million
2,579,737 Added 44.27%
8,407,152 $93.2 Million
Q1 2022

May 16, 2022

BUY
$11.55 - $20.06 $67.3 Million - $117 Million
5,827,415 New
5,827,415 $79.3 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $298M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.